8月8日,中国AI医疗行业头部企业医渡科技(2158.HK)发布《2025年7月通讯》。期内,公司各线主力业务持续推进:参与国家哮喘诊疗重大专项攻关、深圳惠民保参保再创历史新高、辅助雷珠单抗生物类似药申报上市、接连中标跨国药企多个真实世界研究项目等。深度赋能国家哮喘诊疗重大专项“癌症、心脑血管、呼吸和代谢性疾病防治研究”国家科技重大专项“哮喘诊疗管理新体系构建:从易感人群识别、早诊到基于多维度表型...
Source Link8月8日,中国AI医疗行业头部企业医渡科技(2158.HK)发布《2025年7月通讯》。期内,公司各线主力业务持续推进:参与国家哮喘诊疗重大专项攻关、深圳惠民保参保再创历史新高、辅助雷珠单抗生物类似药申报上市、接连中标跨国药企多个真实世界研究项目等。深度赋能国家哮喘诊疗重大专项“癌症、心脑血管、呼吸和代谢性疾病防治研究”国家科技重大专项“哮喘诊疗管理新体系构建:从易感人群识别、早诊到基于多维度表型...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.